NCT06780670 2026-03-16
PSMAcTION
Novartis
Phase 2/3 Recruiting
Clinical Trials
14 trialsNCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT03348670 2025-08-17
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT03706365 2025-04-20
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting
NCT05381103 2025-01-31
PSMA-PET to Guide Prostatectomy
Five Eleven Pharma, Inc.
Phase 2/3 Recruiting
NCT02981368 2021-08-09
OSPREY
Progenics Pharmaceuticals, Inc.
Phase 2/3 Completed
NCT00215683 2015-04-01
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT00295802 2014-02-07
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer
EDAP TMS S.A.
Phase 2/3 Unknown
NCT00332280 2013-03-20
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Auron Healthcare GmbH
Phase 2/3 Terminated
NCT00004071 2012-09-11
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
Pfizer
Phase 2/3 Completed
NCT00268892 2010-12-24
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT00312442 2010-06-02
Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy
STEBA France
Phase 2/3 Terminated
NCT00043576 2009-03-12
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
Novacea
Phase 2/3 Unknown
NCT00127478 2007-11-29
A Long Term Safety Study With Atrasentan
Abbott
Phase 2/3 Completed